AbbVie presents 22 IBD abstracts: stock at EUR 253.15 pre-market
Published on 10/13/2026 at 08:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- AbbVie announced 22 IBD abstracts for the ACG 2026 meeting.
- Phase 3 AFFIRM data showed higher response rates for SKYRIZI versus placebo.
- AbbVie stock was at EUR 253.15 pre-market at Lang & Schwarz.
AbbVie announced on October 11, 2026, that it would present 22 scientific abstracts from its inflammatory bowel disease portfolio at the American College of Gastroenterology 2026 Annual Scientific Meeting. The company’s release said the presentations would include new Phase 3 AFFIRM results for SKYRIZI and real-world evidence on RINVOQ. The stock was at EUR 253.15 at Lang & Schwarz on October 13, 2026, at 8:26 a.m. CEST.
Pre-market trading
AbbVie stock was quoted at EUR 253.15 in pre-market trading at Lang & Schwarz. The bid was EUR 252.60 and the ask was EUR 253.70. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.
Research presented at ACG 2026
According to AbbVie, the AFFIRM study showed that subcutaneous risankizumab achieved higher rates of clinical remission and endoscopic response than placebo at Week 12 in advanced therapy-naive Crohn’s disease patients. The release also reported that 74.5% of patients with fistulizing Crohn’s disease achieved no draining fistulas after five years in an open-label extension analysis. Oral presentations and posters were scheduled across October 11 through October 13, 2026, at the Nashville meeting.
Market context: Market report S&P 500.
